Please login to the form below

Not currently logged in

The Liver Meeting 2019

This page shows the latest The Liver Meeting 2019 news and features for those working in and with pharma, biotech and healthcare.

Novartis makes case for NASH candidate tropifexor

Novartis makes case for NASH candidate tropifexor

This condition is a type of non-alcoholic fatty liver disease (NAFLD), which causes an accumulation of fat in the liver which leads to chronic inflammation and fibrosis. ... The full, detailed data is due to be presented at The Liver Meeting 2019 taking

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts


Add my company
Thrive Agency

We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...

Latest intelligence

New Playbook Alert: Virtual Patient Engagement
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....